understanding glp 1 GLP-1 Therapy Part 1: Setting Realistic Weight Loss Expectations – Sarah Hormachea Current Insights, Advantages and Challenges

Dewangan P, Mourya A, Singh PK, Chaudhary M, Sharma R, Bajwa N, et al

Thats according to a June 2024 study in the Journal of the American Medical Association

[116] Animal experiments suggest doses as high as 250 mg/kg are non-toxic

This is also a percentage change, so the higher the starting uACR, the larger the expected change

But one researcher, John Cawley, a professor of economics and public policy at Cornell University, and his colleagues found that while obesity basically doubles a persons annual health care costs, the savings associated with public insurance plans covering GLP-1s for just obesity treatment are dependent on the patients starting body mass index, or BMI